Newbury Pharmaceuticals AB has published its annual report for the 2022/2023 financial year.

The annual report for 2022/2023 is available to download on the company's website www.newburypharma.com/investors/. The Annual General Meeting will be held on Wednesday, January 10, 2024.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

Newbury Pharmaceuticals Årsredovisning September 2022 Augusti 2023

© Modular Finance, source Nordic Press Releases